Dupilumab may offer long-term eczema control

A study has uncovered the long-term safety and efficacy of dupilumab in patients with atopic dermatitis.

In a study published in Allergy, investigators used real-world data to analyze the outcomes in adult and pediatric patients with moderate-to-severe atopic dermatitis who received dupilumab, tralokinumab, lebrikizumab or nemolizumab.

The investigators found that the patients who received dupilumab experienced high persistence — with up to 90% of adult and pediatric patients remaining on the treatment after three years — reduced pruritus and an enhanced quality of life. Nemolizumab demonstrated rapid itch relief within one week of treatment.

Dupilumab was also found to manage comorbid atopic conditions such as asthma, lower type 2 inflammatory markers, increase skin microbiome diversity and improve skin barrier function. Lebrikizumab helped improve asthma exacerbations in some of the patients.

Although real-world data was abundant for dupilumab, this type of data was limited for the other treatment types included in the study. The investigators hope that upcoming phase III trials can help better inform the use of dupilumab in this patient population.

Read more: Allergy

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.